6214-64-8

Usage

Chemical Properties

White solid

InChI:InChI=1/C8H10N2O3/c1-3-13-7(11)6-4-9-8(12)10-5(6)2/h4H,3H2,1-2H3,(H,9,10,12)

Upstream product

• 17994-55-7 6-methyl-2-oxo-1,2,3,4-tetrahydro-pyrimidine-5-carboxylic acid ethyl ester 
• 141-97-9 ethyl acetoacetate 
• 122-51-0 orthoformic acid triethyl ester 
• 57-13-6 urea 
• 6319-01-3 ethyl 2-acetyl-3-ureido-2-propenoate 
• 3788-94-1 2-ethoxymethylene-3-oxobutanoic acid ethyl ester 
• 452357-80-1 ethyl 4-(trichloro-methyl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate 

Downstream Products

• 5948-72-1 ethyl 6-methyl-2-oxo-4-(2-thienyl)-1,2,3,4-tetrahydropyrimidine-5-carboxylate 
• 17994-56-8 ethyl 4,6-dimethyl-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate 

Relevant academic research and scientific papers

RECYCLIZATION OF 5-CARBETHOXY-4-METHYL-2-MERCAPTO(AMINO, HYDROXY) PYRIMIDINES TO GIVE 5-ACETYL-2-MERCAPTO(AMINO, HYDROXY)-4-HYDROXYPYRIMIDINES

Conditions for the selective preparation of 5-carbethoxy-4-methyl-2-substituted pyrimidines or 5-acetyl-4-hydroxy-2-substituted pyrimidines by condensation of ethoxymethyleneacetoacetic ester with 1,3-binucleophiles are proposed.It is shown that under the influence of sodium ethoxide 5-carbethoxy-4-methyl-2-substituted pyrimidines undergo rearrangement to 5-acetyl-4-hydroxy-2-substituted pyrimidines.

NOVEL COMPOUNDS AS REARRANGED DURING TRANSFECTION (RET) INHIBITORS

This invention relates to novel compounds which are inhibitors of the Rearranged during Transfection (RET) kinase, to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy, alone or in combination, for the normalization of gastrointestinal sensitivity, motility and/or secretion and/or abdominal disorders or diseases and/or treatment related to diseases related to RET dysfunction or where modulation of RET activity may have therapeutic benefit including but not limited to all classifications of irritable bowel syndrome (IBS) including diarrhea-predominant, constipation-predominant or alternating stool pattern, functional bloating, functional constipation, functional diarrhea, unspecified functional bowel disorder, functional abdominal pain syndrome, chronic idiopathic constipation, functional esophageal disorders, functional gastroduodenal disorders, functional anorectal pain, inflammatory bowel disease, proliferative diseases such as non-small cell lung cancer, hepatocellular carcinoma, colorectal cancer, medullary thyroid cancer, follicular thyroid cancer, anaplastic thyroid cancer, papillary thyroid cancer, brain tumors, peritoneal cavity cancer, solid tumors, other lung cancer, head and neck cancer, gliomas, neuroblastomas, Von Hippel-Lindau Syndrome and kidney tumors, breast cancer, fallopian tube cancer, ovarian cancer, transitional cell cancer, prostate cancer, cancer of the esophagus and gastroesophageal junction, biliary cancer, adenocarcinoma, and any malignancy with increased RET kinase activity.

Synthesis of 4-aminoquinoline - Pyrimidine hybrids as potent antimalarials and their mode of action studies

One of the most viable options to tackle the growing resistance to the antimalarial drugs such as artemisinin is to resort to synthetic drugs. The multi-target strategy involving the use of hybrid drugs has shown promise. In line with this, new hybrids of

Facile transformation of Biginelli pyrimidin-2(1H)-ones to pyrimidines. In vitro evaluation as inhibitors of Mycobacterium tuberculosis and modulators of cytostatic activity

A series of pyrimidine derivatives bearing amine substituents at C-2 position were obtained from Biginelli 3,4-dihydropyrimidin-2(1H)-ones and the effect of structural variation on anti-TB activity against Mycobacterium tuberculosis H37Rv strai

Investigation on possibility of rearrangement of pyrimidine-5-carboxylic acids esters

A previously reported rearrangement of pyrimidine-5-carboxylic acids esters to 5-acylpyrimidones does not, in fact, occur in any of the examples studied by us.

A novel convenient synthesis of 5-acyl-1,2-dihydropyrimidin-2-ones via 4-trichloromethyl-1,2,3,4-tetrahydropyrimidin-2-ones

A novel four-step methodology for the synthesis of 5-acyl-1,2-dihydropyrimidin-2-ones has been developed. The reaction of readily available N-[(1-acetoxy-2,2,2-trichloro)ethyl]ureas with Na-enolates of 1,3-diketones or β-oxoesters followed by heterocycliz

An efficacious protocol for 4-substituted 3,4-dihydropyrimidinones: Synthesis and calcium channel binding studies

Ethyl 1,2-dihydro-l, 6-dimethyl/6-methyl-2-oxopyrimidine-5carboxylates react with C-nucleophiles as well as the anion of the enantiopure chiral auxiliary (l R, 2 S,5 R) - (-) - methyl (S)p-toluenesulfinate to afford 4-substituted and enantiopure congeners

An efficacious protocol for the oxidation of 3,4-dihydropyrimidin-2(1H)- ones using pyridinium chlorochromate as catalyst

4-Unsubstituted as well as 4,6-aryl/alkyl-3,4-dihydropyrimidin-2(1H)-ones were oxidized under neutral conditions using pyridinium chlorochromate to obtain the corresponding pyrimidin-2(1H)-ones in a synthetically useful manner.

A highly regio- and chemoselective addition of carbon nucleophiles to pyrimidinones. A new route to C4 elaborated Biginelli compounds

Ethyl 6-methyl-pyrimidine-2-one-5-carboxylates react with C-nucleophiles in a diversity oriented synthetic sequence to afford C4 substituted congeners of medicinally potent Biginelli dihydropyrimidinones, in a highly regioselective manner.

PROCESS FOR THE PRODUCTION OF PYRIMIDINE-5-CARBOXYLATES

Pyrimidine-5-carboxylates of formula wherein R is C1-4 alkyl, R1 is C1_4 alkyl or trifluoromethyl, R2 is hydrogen or C1 alkyl and X is hydroxy, chlorine or bromine, are prepared from 3-oxoalkanoates of formula with urea and orthoesters of formula R2C(OR)3 (III). The intermediate 2-acyl-3-ureidoacrylate, without being isolated, is reacted to give a 2-hydroxypyrimidine-5-carboxylate [(I), X = OH] or a hydrate thereof, which is optionally converted into the corresponding chloro or bromo compound (I, X = Cl, Br).